Edition:
United States

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

77.70EUR
7:15am EDT
Change (% chg)

€-0.05 (-0.06%)
Prev Close
€77.75
Open
€77.55
Day's High
€77.75
Day's Low
€76.85
Volume
25,791
Avg. Vol
81,313
52-wk High
€80.95
52-wk Low
€49.98

Select another date:

Fri, Sep 29 2017

BRIEF-Diasorin revises its FY 2019 guidance

* INCREASES ITS 2019 REVENUE GUIDANCE TO ABOUT EUR 775 MILLION FROM EUR 735 MILLION

BRIEF-DiaSorin ‍completes acquisition of Elisa immunodiagnostic business portfolio​

* ‍COMPLETES ACQUISITION OF ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS HEALTHINEERS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-DiaSorin ‍earns CE-mark extending sample claims for its Simplexa HSV 1&2 kit​

* ‍EARNS CE-MARK EXTENDING SAMPLE CLAIMS FOR DIASORIN MOLECULAR'S SIMPLEXA HSV 1 & 2 KIT​

BRIEF-DiaSorin Q2 net profit up at EUR 33.6 mln

* Q2 NET PROFIT EUR 33.6 MILLION VERSUS EUR 29.4 MILLION YEAR AGO

BRIEF-DiaSorin launches three primer pairs for use in molecular testing

* LAUNCHES 3 PRIMER PAIRS FOR USE IN MOLECULAR TESTING: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, AND GROUP G STREPTOCOCCUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Diasorin to acquire ELISA immunodiagnostic business portfolio from Siemens Healthineers

* TO ACQUIRE ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS HEALTHINEERS

BRIEF-DiaSorin launches test Iam CBFB-MYH11 for acute myeloid leukemia

* LAUNCHES MOLECULAR DIAGNOSTIC TEST IAM CBFB-MYH11 (AVAILABLE WORLDWIDE EXCEPT UNITED STATES) FOR DIAGNOSIS OF ONE OF THE GENETIC CAUSES OF ACUTE MYELOID LEUKEMIA Source text: http://reut.rs/2tZeE1p Further company coverage: (Gdynia Newsroom)

BRIEF-Diasorin presents its 2017-2019 industrial plan

* DIASORIN WILL CONTINUE TO LOOK FOR POTENTIAL ACQUISITIONS, FOCUSING ON TARGET THAT WILL ALLOW GROUP TO EXPAND ITS CUSTOMER BASE AND ITS PRESENCE IN STRATEGIC MARKETS

BRIEF-DiaSorin to collaborate with Tecan in platform development

* UNDER COLLABORATION DIASORIN WILL MAKE USE OF TECAN'S FLUENT LABORATORY AUTOMATION SOLUTION AS ITS NUCLEIC ACID EXTRACTION PLATFORM Source text: http://reut.rs/2sI1hzF Further company coverage: (Gdynia Newsroom)

BRIEF-Diasorin, Qiagen to develop tests for Diasorin's family of analyzers

* Signs collaboration with Qiagen to expand liaison test menu through adoption of select Qiagen assays Further company coverage:

Select another date: